Managing risk in developing transplant immunosuppressive agents: the new regulatory environment

Area of Science:

• Pharmacovigilance
• Regulatory Science
• Drug Safety

Background:

• Recent adverse events with marketed drugs highlight post-approval safety concerns.
• Regulatory bodies have implemented new measures to enhance drug safety surveillance.
• Deficits in drug approval and postmarketing safety systems necessitated legislative action.

Purpose of the Study:

• To outline the objectives and limitations of Risk Evaluation and Mitigation Strategies (REMS) and Postmarketing Requirements (PMRs).
• To examine the potential impact of REMS and PMRs on the clinical specialty of transplantation.
• To briefly describe alternative approaches for managing drug safety issues not covered by REMS and PMRs.

Main Methods:

• Review of regulatory legislation and initiatives.
• Analysis of the framework and application of REMS and PMRs.
• Discussion of implications for clinical practice, particularly in transplantation.

Main Results:

• REMS and PMRs are legal authorities empowering the FDA to enforce drug safety measures.
• These initiatives aim to ensure that pharmaceutical product benefits outweigh risks.
• Healthcare practitioners require further education on REMS and PMRs to address misconceptions.

Conclusions:

• REMS and PMRs represent significant advancements in postmarketing drug safety.
• Understanding and proper implementation of these measures are vital for patient outcomes.
• Ongoing efforts are needed to address all facets of drug safety beyond REMS and PMRs.